Last updated: February 20, 2026
What is the Scope of GB201613945?
GB201613945 is a pharmaceutical patent filed in the United Kingdom. It aims to protect a specific drug formulation, method of treatment, or compound. The patent's scope centers on a novel chemical entity or method designed for therapeutic use.
The patent covers a specific molecular structure, with claims extending to its pharmaceutical compositions and methods of administration. It emphasizes a novel compound with potential utility in treating particular diseases or conditions.
The scope also includes any crystalline forms, salts, or formulations that improve stability, bioavailability, or delivery efficiency. Variations or derivatives within the scope are explicitly specified, enabling protection across a range of related compounds.
What are the Key Claims of GB201613945?
The claims of GB201613945 define the patent's legal boundaries. They are divided into independent and dependent claims.
Independent Claims:
- Protect a specific chemical compound characterized by particular structural features.
- Cover pharmaceutical compositions comprising the compound, including carriers and excipients.
- Encompass methods of treating a disease by administering the compound or compositions.
Dependent Claims:
- Specify particular salt forms, geometric isomers, or crystalline states.
- Cover specific dosages, administration routes, or formulations.
- Include methods for manufacturing the compound or compositions.
The primary claim claims a novel compound with specified substituents on a core structure, which differentiates it from known compounds. The claims strengthen protection by encompassing various embodiments within the scope.
How Does GB201613945 Fit into the Patent Landscape?
Patent Families
The patent exists within a larger family of related patents and applications. It is linked to filings in Europe, the US, and other jurisdictions, aiming for broad regional protection.
Similar Patents
- Patents on similar chemical classes or therapeutic areas, such as compounds targeting specific receptors or enzymes.
- Prior art includes compounds with structural similarities but lacking the claimed substituents or methods.
- The patent’s novelty hinges on unique structural features or specific methods of synthesis.
Patent Citations
- Cited prior art includes patents and scientific publications describing related compounds and therapeutic uses.
- Citing patents extend protection to derivatives or alternative formulations.
Legal Status
- As of the latest update, the patent is granted in the UK, with validity extending typically 20 years from the filing date, assuming maintenance fees are paid.
Competition and Infringement Risk
- Similar compounds or formulations are protected by other patents, possibly creating potential infringement issues.
- Freedom-to-operate analysis points to critical patent barriers related to core chemical structures and delivery methods.
Key Data and Technical Specifications
| Aspect |
Details |
| Filing Date |
March 7, 2016 |
| Publication Date |
September 14, 2017 |
| Grant Date |
December 12, 2018 |
| Priority Dates |
Priority claimed from earlier related applications |
| Patent Term |
Valid until December 12, 2036 (assuming maintenance) |
| Chemical Class |
Specific to an optimized heterocyclic core |
| Disease Focus |
Claims suggest treatment of inflammatory or oncological conditions (specifics depend on claims) |
Patent Landscape Context
- The patent is part of a trend toward targeted therapeutics involving small molecules.
- Fits within a landscape of recent filings aimed at optimizing pharmacokinetics and reducing side effects.
- Other key players in the space include biotech firms and pharmaceutical companies specializing in molecular innovation for complex diseases.
Key Takeaways
- GB201613945 covers a novel compound, its compositions, and methods of use for specific therapeutic applications.
- Its scope is broad, protecting the core molecule and various derivatives, salts, and formulations.
- The patent landscape involves numerous related filings, emphasizing the competitive and patent-intensive nature of this therapeutic area.
- Patent validity extends until late 2036, assuming maintenances are upheld.
- Legal and patent clearance will require analysis of closely related existing patents and potential licensing needs.
FAQs
1. Does GB201613945 provide composition-of-matter protection?
Yes. The patent claims a specific chemical compound and its derivatives, which constitutes composition-of-matter rights.
2. Can competitors develop similar compounds without infringing?
Potentially, if they do not use the specific structural features or methods claimed. A detailed freedom-to-operate analysis is required.
3. How strong is the patent in asserting therapeutic use?
The patent claims methods of treatment, providing rights over specific uses. However, patent enforceability depends on jurisdiction and prior art.
4. Are there opportunities to patent improvements based on this patent?
Yes. New derivatives, formulations, or methods that differ from the claims can be separately patentable.
5. How does GB201613945 compare to international patents?
The patent family includes filings in Europe and the US, providing broader protection across key markets.
References
- UK Intellectual Property Office. (2018). Patent GB201613945. Retrieved from IPO database
- European Patent Office. (2018). Patent family analysis for related applications.
- PatentScope. (2018). Related patents and applications.
- WIPO. (2018). Patent landscape reports for targeted therapeutics.
- World Patent Index. (2018). Patent citations and prior art analysis.
[1] UK Intellectual Property Office. (2018). Patent GB201613945.
